Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

By sjmartinez • August 2, 2022

Wander SA, O'Brien N, Litchfield LM, O'Dea D, Morato Guimaraes C, Slamon DJ, Goel S. Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. Oncologist. 2022 Aug 2:oyac138. doi: 10.1093/oncolo/oyac138. Epub ahead of print. PMID: 35917168.

Tags: abemaciclib, antitumor, breast neoplasms, CDK4 and 6, Hematology/Oncology, preclinical, Publications

Related Posts

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin[...]

Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer

Zhang S, Queen KJ, Duggirala N, Yang E, Lipsyc-Sharf M, Racz J, Bennett J, Hong K, Suresh Y, Hamilton C, Pitta M, Chien N, La[...]

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer

Choueiri TK, Merchan J, Patnaik A, Drakaki A, Rini BI, Rha SY, Lee JL, Ornstein MC, Kumar R, Hwang C, Shao Y, Park SH, Barata[...]